Physician profile
James A Winter
NPI 1205890795
$484.48
in general payments reported to CMS, 2019-2025
12 companies · $80.66 in 2025
The $80.66 reported for 2025 was more than what a typical Anatomic Pathology & Clinical Pathology provider received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $131 · 2023: $172 · 2024: $101 · 2025: $80.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $353.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $114.78 | 2022-2023 | Padcev |
| Servier Pharmaceuticals LLC | $79.37 | 2023-2025 | |
| Roche Diagnostics Corporation | $50.12 | 2022 | |
| Genentech USA, INC. | $49.52 | 2024 | Tecentriq, Alecensa, Tecentriq Hybreza |
| Novartis Pharmaceuticals Corporation | $48.78 | 2023 | |
| Jazz Pharmaceuticals INC. | $34.84 | 2023-2025 | |
| Daiichi Sankyo INC. | $26.14 | 2025 | Enhertu |
| Pfizer INC. | $17.75 | 2024 | |
| Abbvie INC. | $16.54 | 2025 | |
| Myriad Genetic Laboratories, INC. | $16.00 | 2023 | Myrisk |
| Astrazeneca Pharmaceuticals LP | $15.80 | 2024 | Tagrisso |
| Merck Sharp & Dohme LLC | $14.84 | 2023 | Keytruda, Lynparza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Winter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.